BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus and growth-oriented investments and capital allocation for both BD and the separated business and enhance value creation for shareholders.
Reports Q1 revenue $5.2B, consensus $5.11B. “We delivered strong operational performance in Q1, with revenue growth, margin expansion and ...
U.S. medical device maker Becton Dickinson is considering a potential separation of its life sciences unit at a valuation of ...
Medical technology company Becton, Dickinson and Company (NYSE:BDX) will be announcing earnings results tomorrow before market open. Here’s what to look for.
Becton Dickinson & Co. closed 2.75% below its 52-week high of $251.99, which the company reached on February 3rd.
Shares of Becton, Dickinson and Company (NYSE:BDX – Get Free Report) have earned an average rating of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports ...
While the top- and bottom-line numbers for Becton Dickinson (BDX) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key ...
Learn more about whether Becton, Dickinson and Company or Intuitive Surgical, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Company will spotlight sustainable solutions to enhance patient safety, workforce well-being, and care delivery efficiency ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback